全球知识产权每日洞察 — 2026-06-26

中国企业(1 篇)

ipfray.com 2026-06-25

UK-based Ocado Group licenses grocery technology, such as automated warehousing, e-commerce platform software, and operational data. It also owns a 50% share in the online grocery retail business Ocado.com.

The company’s IP team manages a portfolio of over 1,900 active granted patents, as well as 1,800 pending applications, across nearly 500 families. They are chiefly filed in one or a mix of the U.S., Europe, Canada, Australia, China, Japan, and Korea – with some also filed in emerging jurisdictions such as Brazil, Indonesia, and Malaysia. Ocado is one of the very few overseas businesses that has now also enforced patents in Malaysia, which may be seen as a more “whacky” choice, Lucy Wojcik, who has served as the company’s Chief IP Counsel for over a decade, told

ip fray

during an interview at

IP Dealmakers Europe

中国企业 SEP/FRAND 法律裁决

SEP/FRAND(2 篇)

ipfray.com 2026-06-25

Context:

The World Intellectual Property Organization (WIPO) has recently rolled out several updates to its patent search database, PATENTSCOPE, in an effort to improve transparency around standard-essential patent (SEP) ownership (

April 30, 2025 WIPO announcement

).

What’s new and direct impact:

SEP/FRAND 法律裁决

科技巨头(1 篇)

ipfray.com 2026-06-25

Context:

CareFirst of Maryland, Inc. filed a putative class action against Johnson & Johnson in December 2023, alleging that Johnson & Johnson willfully maintained its monopoly over Stelara (ustekinumab), a biologic drug used to treat psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease, in violation of Section 2 of the Sherman Act. The theory centers on Johnson & Johnson’s 2020 acquisition of Momenta Pharmaceuticals and its later assertion of Momenta’s patent portfolio against Amgen, Inc. and other ustekinumab biosimilar makers. The United States District Court for the Eastern District of Virginia (Judge Jamar K. Walker) initially denied Johnson & Johnson summary judgment on that theory, then reversed itself on reconsideration, holding that CareFirst needed to show Johnson & Johnson specifically intended to exclude rivals. CareFirst appealed to the U.S. Court of Appeals for the Fourth Circuit in 2025.

To Read The Full Story

Sign In

Continue reading your article with a Membership

法律裁决
Tweaks